Researchers in Pennsylvania conducted a randomized controlled trial to understand the effect of patient outreach on lung cancer screening rates.
New findings from a randomized controlled trial revealed outreach contacts significantly increased lung cancer screening (LCS) among primary care patients across 4 practices in Pennsylvania. Results were published in Preventive Medicine.
Although previous data has indicated periodic low dose computed tomography (LDCT) screening can significantly reduce lung cancer mortality, LCS rates are low in the United states with one assessment concluding the current rate among eligible patients is 4.5%, compared with a 7.5% target goal, researchers explained.
CMS does cover the service for individuals aged 55 to 77 and “have at least a 30 pack-year smoking history and currently smoke, or have a history of heavy smoking but have quit smoking within the past 15 years,” as recommended by the United State Preventive Service Task Force (USPSTF).
But the agency also requires shared decision making (SDM) about LCS prior to completion, an infrequent occurrence in clinical practice, according to authors.
In an effort to determine the effects of patient outreach and SDM strategies on LCS uptake, investigators conducted a randomized controlled trial of patients receiving care at Jefferson Health in Pennsylvania.
Of the 4 practices included in the study, 2 were Family and Community Medicine practices and 2 were Internal Medicine practices. In addition, “2 practices (1 Family and Community Medicine and 1 Internal Medicine) served primarily English-speaking white and African American patients. One Family and Community Medicine practice served primarily Chinese patients, and the remaining Internal Medicine practice served mostly Korean patients,” authors wrote.
Eligible participants were identified via electronic medical record (EMR) data, and patients were randomized to an outreach contact plus decision counseling (OC-DC) group, an outreach contact alone (OC) group, or usual care control group (UC).
A total of 2347 patients were included in the final analyses with 302 in the OC-DC group, 297 in the OC group and 1748 in the UC group. A slim majority of patients (52%) were female while 31% were African American and 7% were Asian.
Analyses revealed:
Overall, screening completion was significantly higher among those who received some form of outreach contact compared with patients receiving usual care. This could be due to an increase in LCS referral and scheduling for the service. While SDM incorporation appeared to have an additive effect, more research is needed to assess this addition to care.
“Even when extended follow-up (up to 9 months) was considered, during which many of the usual care group participants were likely to have had a routine care visit with their provider, their LCS screening rate did not catch up with that of the intervention groups,” authors noted.
Due to limited data in EMRs, researchers were unable to ascertain intervention impact among those with verified LCS eligibility, marking a limitation to the study. Generalizability of findings may also be limited and may not apply to all primary care practices.
Reference:
DiCarlo M, Myers P, Daskalakis C, et al. Outreach to primary care patients in lung cancer screening: a randomized controlled trial. Prev Med. Published online April 22, 2022. doi:10.1016/j.ypmed.2022.107069
California Aims for Equity by Redefining Cancer Care
December 8th 2023Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Patients With RA in Remission Withdrawing From TNF Inhibition Show Flare Increases
December 8th 2023New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued a tumor necrosis factor inhibitor (TNFi).
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Research Reveals the Role of Structural Racism in Lung Cancer Risk
December 7th 2023Spanning 22 studies, the analysis illuminated housing disparities, occupational hazards, unequal health care access, economic inequality, and discriminatory industry practices and how they collectively contribute to heightened lung cancer risks.
Read More
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More